Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (17251)	3/11/1998 5:20:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

Tuck and Henry: The following news from lly does not seem to fit the LGND criteria, but I thought I would note it just in case....Walter ELI LILLY CANADA INC. - NEW HOPE FOR PATIENTS WITH MOST DIFFICULT FORM OF CANCER - FIRST NEW CHEMOTHERAPY AGENT IN 30 YEARS FOR PANCREATIC CANCER GEMZAR(R) IS NOW APPROVED FOR THIS INDICATION PS Details on Yahoo.

To: tuck who wrote (17251)	3/17/1998 6:29:00 PM
From: tuck	Read Replies (3) \| Respond to of 32384

Folks, As of late February to early March, it was very probably a SERM. Does the extension agreement of March 9th imply it is still a SERM or not? That is the question. If so, I'd venture that they are trying to get the Canadian rights to Evista or some similar deal. Any guesses on the size of Evista or other SERM market up there? What are the costs to Ligand to market it there? I.E. Can we calculate a ballpark estimate of the earnings streams? Who would manufacture the product? Tuck